Tauriga Sciences, Inc. (TAUG) Differentiating Features Integrated into its Cannabis/CBD Infused Chewing Gum Product Line

Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, has today revealed several of the specific & differentiating features integrated into its Cannabis/CBD chewing gum product line (“CBD Gum”).  In a recent press release, the Company mentioned that it had conceived its CBD Gum product line, by implementing the advice that several prospective distributors had recommended to management.

Integrated into Tauriga’s CBD Gum Product line, are the following specifically integrated features:

1. Tauriga’s CBD Gum product line is Gluten-Free
2. Tauriga’s CBD Gum product line is manufactured – Non-Genetically Modified Organisms (“Non-GMO”)
3. Tauriga’s CBD Gum product line is Allergen-Free
4. Tauriga’s CBD Gum product line is VEGAN
5. Tauriga’s CBD Gum product line will be KOSHER (Star-K Kosher Certification)
6. Tauriga’s CBD Gum product line will be PAREVE (Non-Dairy)
7. Tauriga’s CBD Gum product line will initially be available in COOL MINT
8. Tauriga’s CBD Gum product line will only be sold to customers of age 18 or older

In other news, the Company has selected the following name under to which to brand its CBD Gum product line: Tauri-GUM.  Several weeks ago, the Company confirmed that it had applied for (“filed for”) this above-referenced trademark with the United States Patent & Trademark Office (“U.S.P.T.O.”); the Company’s Trademark Application has been assigned the serial # 88/226,543.  The Company has also been focused on the creation of its Logo (Tauri-Gum brand) and the completion of the artwork and graphic design(s) for both the outer product package (individual pack) as well as the display cases (for retail locations).  Once this creative work has been completed, the Company will disclose its Logo and graphic design artwork to its shareholders (through a press release).

AN IMPORTANT COMMITMENT:  The Company wishes to confirm to its shareholders, that at all times, it will remain in compliance with both U.S. Federal and individual State rules and regulations & laws that govern this sector.  At the same time, the Company will be constantly monitoring the legal landscape which may experience material change(s), at any point in the future.

Studies have shown that a chewing gum product may provide a superior delivery method for distributing its key active ingredients (such as CBD), in comparison to other oral dosage forms, such as: pills, capsules, beverages, and gummies.  As an individual chews gum, the CBD is released from the gum quickly and is absorbed by the Oral Mucosa, rather than the Digestive System.  Bypassing the Digestive Tract allows the CBD to maintain its inherent bioavailability, and it also means that the CBD gets absorbed by the body – substantially faster than other forms of Oral Ingestion.  Studies have also shown that CBD that is swallowed as capsules, beverages, gummies or edibles delivers less than 10% of the CBD shown on each respective label.  With CBD Infused Chewing Gum, an individual can get relief for aches and pains in rapid time, and at a dose that is potentially strong enough to make a noticeable difference, and delivered cost effectively without wasting the majority of the CBD consumed.

ABOUT:    TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is currently evaluating potential acquisition candidates, as previously disclosed, to create lasting shareholder value. Additionally, the Company is working diligently to identify potential opportunities to generate revenue and leverage its considerable resources and expertise to build a diversified and sustainable business model.  Please visit our corporate website at www.tauriga.com

Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:
CONTACT INFORMATION

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY  10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:  sshaw@tauriga.com
cell # (917) 796 9926
www.tauriga.com